Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine for Cognitive Function and Inflammation in Major Depression
NCT01391221Phase 4Unknown
- Sponsor
- Institut Universitaire en santé Mentale de Montréal
- Start
- Jul 2011
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of duloxetine in major depressive disorder (MDD), sponsored by Institut Universitaire en santé Mentale de Montréal. Primary endpoint: Cognitive function measured by CANTAB at 12 weeks. Status: unknown.
02
Drugs
duloxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01391221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01391221.